UNSPSC 51281821: Idarubicin hydrochloride

This classification denotes an anthracycline antibiotic with the molecular formula C26H27NO9.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5VV3MDU5IE, chemically known as daunomycin, 4-demethoxy-, hydrochloride but more generally known as idarubicin hydrochloride, which bears US NIH Compound Identifier 3685. European Medicines Agency schedules Idarubicin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02635MIG.

UNSPSC 51281821 Idarubicin hydrochloride is a Commodity code that in recent state and local procurement activity maps primarily to broader pharmaceutical supply contracts rather than this specific cytotoxic agent alone. State and local health agencies, fire departments, and cooperative purchasing alliances are actively soliciting generic pharmaceuticals, over-the-counter products, and emergency medical supplies through formal competitive processes. The work includes establishing framework agreements with pharmaceutical manufacturers and wholesalers to supply identified products across multiple jurisdictions and facilities, with vendors required to meet cGMP certification, FDA compliance, Drug Supply Chain Security Act (DSCSA) adherence, and specific insurance and shelf-life requirements. Issuing bodies span state health and human services commissions, county health departments, municipal fire departments, and multistate cooperative purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and the Texas Health and Human Services Commission represent large-scale buyers consolidating pharmaceutical procurement across multiple states and agencies.

Recent activity shows geographic concentration in Texas, Minnesota (serving multiple states including Oregon), and Florida. The Minnesota Department of Administration's MMCAP RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) sought manufacturers to supply through authorized wholesalers with pricing effective July 1, 2026 and a two-year initial contract term. Seminole County, Florida issued an IFB for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023) requiring quarterly deliveries of 1,900 units of naloxone and 800 deactivation systems annually with an estimated two-year initial term. The City of Tampa's IFB for medical and first aid supplies (26P00145, due March 13, 2026) encompassed 169 line items totaling an estimated $700,000.00 for the Tampa Fire Department Rescue Division, with a Small Local Business Enterprise set-aside designation and 5 percent bid discount available for certified SLBEs. The Texas HHS Commission's RFI on direct-to-manufacturer prescriptions (HHS0017013, posted April 3, 2026) represents preliminary market intelligence gathering to inform future formal solicitation strategy. The code shows moderate recent activity concentrated in multistate cooperative vehicles and emergency-response supply chains rather than specialized oncology pharmaceuticals.